Welcome to our dedicated page for NORD ANGLIA ED news (Ticker: NORD), a resource for investors and traders seeking the latest updates and insights on NORD ANGLIA ED stock.
NORD ANGLIA ED (NORD) delivers premium international education through innovative blended learning models and a global network of schools. This news hub provides investors and education stakeholders with timely updates on the company's strategic initiatives, financial performance, and academic developments.
Access authoritative reporting on earnings announcements, partnership agreements, curriculum enhancements, and operational expansions. Our curated collection ensures you stay informed about NORD updates including technology integrations, regional market entries, and leadership changes that shape this education leader's trajectory.
Key coverage areas span quarterly results, institutional collaborations, pedagogical innovations, and sustainability initiatives. All content undergoes rigorous verification to maintain factual accuracy while avoiding speculative commentary.
Bookmark this page for streamlined access to NORD's evolving story. Combine regular monitoring with our historical archive to analyze long-term patterns in educational leadership and global market positioning.
Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.
QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.
Orocidin A/S, a subsidiary of Nordicus Partners (NORD), has introduced a breakthrough dental gel for long-term periodontitis treatment. The innovative low-viscosity gel features a unique active peptide and is designed for direct application into dental pockets by dentists using a syringe and flushing cannula.
The gel's key innovation lies in its formulation of triglycerides, monoglycerides, and water. Upon contact with oral cavity moisture, it forms a semi-solid bioadhesive crystalline matrix, enabling slow and localized release of the active ingredient. All components are biocompatible and FDA-approved for oral use.
Nordicus Partners (NORD) announced that its subsidiary, Orocidin A/S, will begin its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to be completed by Q3 2025, enabling the launch of the first pilot efficacy study in patients by year-end.
Orocidin is a proprietary treatment for periodontitis that addresses three key challenges: inflammation reduction, bacterial infection elimination, and bone/teeth regeneration. The company has filed patent applications to protect the product's innovative design.
The development represents a significant milestone in bringing this dental health solution to market, targeting an unmet medical need.
Nordicus Partners (OTCQB:NORD) has announced that its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert ApS, plan to initiate pilot efficacy studies in 2025. These studies will focus on patients with periodontitis and oral leukoplakia. The company clarified that both subsidiaries are currently in the preclinical phase, correcting information provided in previous press releases.
Nordicus Partners (OTCQB:NORD) announced that FINRA has removed the appending 'D' from its OTC equity symbol following the completion of a 20-day transition period related to its previously announced reverse split. The company's common stock will continue trading on the OTCQB market under the symbol 'NORD' starting December 9, 2024. The new CUSIP number following the reverse stock split is 28265K 304. Nordicus is a financial consulting company that specializes in helping Nordic and U.S. life sciences companies establish themselves in the U.S. market.
Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment. The transaction involves 200,000 restricted common shares of Nordicus in exchange for the outstanding Orocidin shares, making Orocidin a 100% wholly-owned subsidiary of Nordicus. The deal strengthens Nordicus's position in facilitating Nordic and U.S. life sciences companies' establishment in the U.S. market.
Nordicus Partners (OTCQB: NORD) has announced an agreement to acquire Bio-Convert ApS, a Denmark-based clinical-stage biopharmaceutical company, in an all-stock transaction of 12 million restricted common shares. Bio-Convert specializes in developing treatments for oral leukoplakia, a potentially malignant disorder that can lead to oral cancer. The company is developing a proprietary mucoadhesive oral formulation that delivers medication without systemic absorption, aiming to eliminate lesions or reduce the malignant conversion rate to oral cancer. Bio-Convert plans to conduct a pilot efficacy study in patients with oral leukoplakia.
Nordicus Partners (OTCQB: NORD) announced a 1-for-10 reverse stock split of its common stock, effective November 8, 2024. The company's stock will continue trading on OTCQB under the symbol 'NORD' with a new CUSIP number 28265K 304. The reverse split was approved by stockholders and the Board of Directors on June 7, 2024. Transfer Online, Inc. will act as the transfer agent, and stockholders are not required to take any action as positions will be automatically adjusted.
Nordicus Partners (OTCQB: NORD) will host an investor relations webinar on July 10, 2024, at 9:00 AM Pacific time. The event will feature presentations by CEO Henrik Rouf and Chairman Peter Severin, who will elaborate on the company’s mission and investment strategy. Allan Wehnert, CEO of Nordicus’ 95% subsidiary Orocidin, will update attendees on Orocidin’s scientific progress. Additionally, details about Nordicus’ accelerator client, Bio-Convert, will be discussed. Interested participants can register for the webinar at the provided link.
Nordicus Partners (OTCQB: NORD), a financial consulting firm, has signed a Consultancy Agreement with Danish biopharmaceutical company BIO-CONVERT. BIO-CONVERT specializes in developing treatments for oral leukoplakia, a potentially cancerous condition. The partnership aims to help BIO-CONVERT establish a U.S. market presence. CEO Henrik Rouf expressed optimism about the collaboration and potential equity investment in BIO-CONVERT. BIO-CONVERT's innovative drug, QR-02, uses advanced technology for precise treatment of oral leukoplakia, potentially preventing oral cancer. The company plans a pilot efficacy study for QR-02.
FAQ
What is the current stock price of NORD ANGLIA ED (NORD)?
What is the market cap of NORD ANGLIA ED (NORD)?
